RGLS Stock Overview
A clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Regulus Therapeutics Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.79 |
52 Week High | US$3.79 |
52 Week Low | US$1.08 |
Beta | 1.64 |
11 Month Change | -22.05% |
3 Month Change | -36.25% |
1 Year Change | 21.43% |
33 Year Change | -77.94% |
5 Year Change | -86.48% |
Change since IPO | -99.65% |
Recent News & Updates
Recent updates
Regulus surges 15% after Phase 1 data for kidney disease candidate
Sep 12Regulus Therapeutics GAAP loss per share narrows
Aug 11Does Regulus Therapeutics (NASDAQ:RGLS) Have A Healthy Balance Sheet?
Oct 12The Read On Regulus Therapeutics
Aug 03We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Regulus Therapeutics Inc.'s (NASDAQ:RGLS) CEO For Now
Jun 09Regulus reports top-line data from early-stage RGLS4326 trial in polycystic kidney disease
May 03Auditors Are Concerned About Regulus Therapeutics (NASDAQ:RGLS)
Mar 13Introducing Regulus Therapeutics (NASDAQ:RGLS), The Stock That Zoomed 101% In The Last Year
Mar 10Regulus Therapeutics announces closing of $19.4M private placement
Dec 08Regulus Therapeutics EPS beats by $0.17, beats on revenue
Nov 05Shareholder Returns
RGLS | US Biotechs | US Market | |
---|---|---|---|
7D | -28.9% | -0.7% | 0.07% |
1Y | 21.4% | 10.2% | 20.7% |
Return vs Industry: RGLS exceeded the US Biotechs industry which returned 10% over the past year.
Return vs Market: RGLS matched the US Market which returned 20.7% over the past year.
Price Volatility
RGLS volatility | |
---|---|
RGLS Average Weekly Movement | 11.6% |
Biotechs Industry Average Movement | 10.4% |
Market Average Movement | 5.7% |
10% most volatile stocks in US Market | 15.3% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: RGLS's share price has been volatile over the past 3 months.
Volatility Over Time: RGLS's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2007 | 28 | Jay Hagan | www.regulusrx.com |
Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies.
Regulus Therapeutics Inc. Fundamentals Summary
RGLS fundamental statistics | |
---|---|
Market cap | US$116.86m |
Earnings (TTM) | -US$31.37m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.7x
P/E RatioIs RGLS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
RGLS income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$22.27m |
Gross Profit | -US$22.27m |
Other Expenses | US$9.10m |
Earnings | -US$31.37m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.48 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.5% |
How did RGLS perform over the long term?
See historical performance and comparison